Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:23:45 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:AMGN from 2023-05-03 to 2024-05-02 - 61 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 07:00U:AMGNNews ReleaseAMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
2024-04-29 16:00U:AMGNNews ReleaseAMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
2024-04-26 09:00U:AMGNNews ReleaseAMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
2024-04-16 17:26U:AMGNNews ReleaseAMGEN TO PRESENT TEZSPIRE(TM) PHASE 2A COPD DATA AT ATS 2024
2024-03-09 12:20U:AMGNNews ReleaseAMGEN PRESENTS NEW RESEARCH ON OTEZLA(TM) (APREMILAST) AT AAD 2024
2024-03-06 16:00U:AMGNNews ReleaseAMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
2024-02-29 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
2024-02-26 09:00U:AMGNNews ReleaseAMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
2024-02-19 16:00U:AMGNNews ReleaseAMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
2024-02-09 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
2024-02-06 16:01U:AMGNNews ReleaseAMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
2024-02-01 16:00U:AMGNNews ReleaseAMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
2024-01-29 05:00U:AMGNNews ReleasedeCODE genetics: A sequence variant that increases risk of pregnancy loss
2024-01-29 05:00U:AMGNNews ReleasedeCODE genetics: A sequence variant that increases risk of pregnancy loss
2024-01-09 10:25U:AMGNNews ReleaseGlobal Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
2024-01-03 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2023-12-26 09:00U:AMGNNews ReleaseAMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS ‚ ® (SOTORASIB)
2023-12-14 09:00U:AMGNNews ReleaseAMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION
2023-12-14 05:00U:AMGNNews ReleaseAMGEN TO SPONSOR THE IRISH OPEN
2023-12-13 16:00U:AMGNNews ReleaseFDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
2023-12-12 16:00U:AMGNNews ReleaseAMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
2023-12-08 09:00U:AMGNNews ReleaseAMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
2023-11-22 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
2023-11-10 09:00U:AMGNNews ReleaseAMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
2023-11-07 16:05U:AMGNNews ReleaseAMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
2023-11-07 16:00U:AMGNNews ReleaseAMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJ ƒ –GREN'S SYNDROME AT ACR 2023
2023-11-02 08:00U:AMGNNews ReleaseAMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA ‚ ® (PEGLOTICASE)
2023-11-01 09:00U:AMGNNews ReleaseAMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
2023-10-31 07:00U:AMGNNews ReleaseAMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
2023-10-25 16:00U:AMGNNews ReleaseAMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
2023-10-24 16:00U:AMGNNews ReleaseAMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND
2023-10-22 10:30U:AMGNNews ReleaseAMGEN PRESENTS NEW LUMAKRAS ‚ ® (SOTORASIB) PLUS VECTIBIX ‚ ® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
2023-10-20 08:00U:AMGNNews ReleaseAMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
2023-10-19 16:00U:AMGNNews ReleaseAMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023
2023-10-16 09:00U:AMGNNews ReleaseAMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
2023-10-12 09:00U:AMGNNews ReleaseGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
2023-10-06 08:30U:AMGNNews ReleaseAMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
2023-10-04 11:00U:AMGNNews ReleaseLarge-scale proteomics in population-based studies from UK and Iceland
2023-09-20 16:00U:AMGNNews ReleaseAMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
2023-09-11 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
2023-09-10 09:00U:AMGNNews ReleaseAMGEN PRESENTS NEW LUMAKRAS ‚ ® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
2023-09-07 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
2023-09-01 09:20U:AMGNNews ReleaseAmgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
2023-09-01 09:20U:AMGNNews ReleaseAMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
2023-08-31 19:30U:AMGNNews ReleaseAMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE
2023-08-26 10:45U:AMGNNews ReleaseAMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
2023-08-21 16:00U:AMGNNews ReleaseAMGEN TO DISCUSS APPLICATION FOR LUMAKRAS ‚ ® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
2023-08-03 16:01U:AMGNNews ReleaseAMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS
2023-08-01 16:00U:AMGNNews ReleaseAMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND
2023-07-31 16:00U:AMGNNews ReleaseAMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS
2023-06-21 09:00U:AMGNNews ReleaseFDA GRANTS FULL APPROVAL FOR BLINCYTO ‚ ® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
2023-06-09 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
2023-06-04 08:00U:AMGNNews ReleaseAMGEN PRESENTS NEW LUMAKRAS ‚ ® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023
2023-06-01 09:00U:AMGNNews ReleaseAMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
2023-05-30 18:00U:AMGNNews ReleaseAMGEN PRESENTS NEW RESEARCH ON OTEZLA ‚ ® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023
2023-05-26 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT
2023-05-16 11:31U:AMGNNews ReleaseAMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS
2023-05-09 09:00U:AMGNNews ReleaseAMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE
2023-05-09 09:00U:AMGNNews ReleaseAmgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn ¢ € ™s Disease
2023-05-08 09:00U:AMGNNews ReleaseNEW DATA FROM AMGEN'S PROLIA ‚ ® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
2023-05-03 16:00U:AMGNNews ReleaseAMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE